Analysts say they expect more tie-ups are coming in the generic drug industry in the wake of Teva's mammoth deal for the generic drug business of Allergan ... or $232.23 per share in cash and Mylan stock. Perrigo disputed the value of …
In the U.S., Mylan and Biocon's Ogivri is the first biosimilar version ... TTPH closed Tuesday's trading at $5.43, down 0.55%. In after-hours, the stock fell 55.06% to $2.44.
Mylan could be facing another issue when it comes to the EpiPen, a drug used to treat severe allergic reactions that …
Mylan N.V. (MYL) cut its 2017 guidance, as a result of expected delays in the timing of certain key new product launches. In the Wednesday's pre-market trade, MYL is trading at $28.90, down $2.89 or 9.09 percent. The company now …
Pharma giant Mylan has agreed to pay the federal government $465 million to settle questions of how the company’s EpiPen was classified under the Medicaid Drug Rebate Program. Mylan announced the deal late on Friday afternoon. …
Generic drug firm Mylan has offered to buy over-the-counter rival Perrigo in a cash and stock deal that would create a pharmaceutical powerhouse. The global drug firm is offering nearly $30bn (£20bn; €28bn) for Ireland-based Perrigo, …
Mylan is the worst-performing stock in the 61-member S&P 500 health-care index over the past 12 months with a 39 percent slump. Perrigo Co., another maker of generics, saw the second-biggest decline at 32 percent, while the …
Cecil-based generic drug maker Mylan Inc. yesterday reported a $1.38 billion loss for the quarter ended Dec. 31 and announced a restructuring that includes shrinking operations, selling the rights to its hypertension drug and the …
Coury. Be the first to know - Join our Facebook page. Teva offered to buy all outstanding Mylan shares for $82, some 48 percent above its March 10 price, in a halfcash, half-stock deal that it said would lead to $2b. in cost savings. Scooping …